产品封面图

AZD9291

收藏
  • ¥500 - 800
  • 自有
  • 上海
  • SYSBC014
  • 2025年07月08日
    • 详细信息
    • 询价记录
    • 文献和实验
    • 技术资料
    • 保质期

      2年

    • 英文名

      (Mereletinib mesylate; EGFR inhibitor; AZD9291 mesylate; AZD 9291 mesylate)

    • 库存

      1kg 库存

    • 曾用名

      (Mereletinib mesylate; EGFR inhibitor; AZD9291 mesylate; AZD 9291 mesylate)

    • 产品用途

      肺癌

    • 规格

      99%

    英文名 AZD-9291 mesylate
    别名 N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide methanesulfonate (1:1)
    产品名称 AZD-9291 甲磺酸盐
    分子结构
    分子式 C28H33N7O2.CH4O3S
    分子量 595.71
    CAS 登录号 1421373-66-1

    AZD-9291 mesylate的生物活性

    AZD-9291 is a potent and selective mutated forms EGFR inhibitor(Exon 19 deletion EGFR IC50=12.92 nM, L858R/T790M EGFR IC50= 11.44 nM, wild type EGFR IC50= 493.8 nM).
    IC50 value: 12.92 nM(Exon 19 deletion EGFR); 11.44 nM(L858R/T790M EGFR) [1]
    Target: L858R/T790M EGFR; Exon 19 deletion EGFR
    AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors. AZD9291 is highly active in preclinical models and is well tolerated in animal models. It inhibits both activating and resistant EGFR mutations while sparing the normal form of EGFR that is present in normal skin and gut cells, thereby reducing the side effects encountered with currently available medicines.
    Patent: WO 2013014448

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    • 作者
    • 内容
    • 询问日期
    图标文献和实验
    相关实验
    图标技术资料

    暂无技术资料 索取技术资料

    AZD9291
    ¥500 - 800